Teva Pharmaceutical Industries Limited
TEVA
$26.88
$0.160.60%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 433.00M | 282.00M | 214.00M | -217.00M | -437.00M |
| Total Depreciation and Amortization | 249.00M | 251.00M | 244.00M | 269.00M | 259.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 248.00M | 30.00M | 137.00M | 768.00M | 554.00M |
| Change in Net Operating Assets | -561.00M | -336.00M | -700.00M | -245.00M | 317.00M |
| Cash from Operations | 369.00M | 227.00M | -105.00M | 575.00M | 693.00M |
| Capital Expenditure | -136.00M | -96.00M | -127.00M | -129.00M | -148.00M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 0.00 | -- |
| Divestitures | 8.00M | 9.00M | 17.00M | 4.00M | 38.00M |
| Other Investing Activities | 263.00M | 323.00M | 311.00M | 327.00M | 378.00M |
| Cash from Investing | 135.00M | 236.00M | 201.00M | 202.00M | 268.00M |
| Total Debt Issued | -- | 2.31B | -- | -- | -- |
| Total Debt Repaid | -451.00M | -2.30B | -1.37B | -685.00M | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.00M | 1.00M | -376.00M | 11.00M | -- |
| Cash from Financing | -453.00M | 6.00M | -1.74B | -674.00M | -- |
| Foreign Exchange rate Adjustments | -9.00M | -5.00M | 45.00M | -121.00M | 100.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -1.00M | -- |
| Net Change in Cash | 42.00M | 464.00M | -1.60B | -19.00M | 1.06B |